We are live on ! Find out more
TLSI icon

TriSalus Life Sciences

68 hedge funds and large institutions have $198M invested in TriSalus Life Sciences in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 18 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

3% more funds holding

Funds holding: 6668 (+2)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1% less ownership

Funds ownership: 81.46%80.46% (-1%)

2% less capital invested

Capital invested by funds: $202M → $198M (-$3.98M)

56% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 18

Holders
68
Holders Change
+2
Holders Change %
+3.03%
% of All Funds
1.05%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
11
Increased
8
Reduced
18
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
GH
51
GAM Holding
Switzerland
$316K
Creative Planning
52
Creative Planning
Kansas
$247K
AA
53
AlphaCentric Advisors
Puerto Rico
$247K +$248K +25,000 New
GCWM
54
Graham Capital Wealth Management
District of Columbia
$226K +$225K +22,679 New
TCM
55
Tenor Capital Management
New York
$198K
CI Investments Inc
56
CI Investments Inc
Ontario, Canada
$192K
Geode Capital Management
57
Geode Capital Management
Massachusetts
$183K
State Street
58
State Street
Massachusetts
$113K +$113K +11,409 New
Walleye Capital
59
Walleye Capital
New York
$112K -$11.1K -1,119 -9%
AA
60
Ancora Advisors
Ohio
$62K +$11.9K +1,200 +24%
PCM
61
Penserra Capital Management
California
$54K +$54.6K +5,493 New
Carson Wealth (CWM LLC)
62
Carson Wealth (CWM LLC)
Nebraska
$49K +$49.7K +5,000 New
ACA
63
Arena Capital Advisors
California
$42K
Morgan Stanley
64
Morgan Stanley
New York
$40K -$1.53K -154 -4%
UBS Group
65
UBS Group
Switzerland
$14K +$14.4K +1,446 +24,100%
TRCT
66
Tower Research Capital (TRC)
New York
$13K +$6.39K +643 +93%
DFCM
67
Dark Forest Capital Management
Puerto Rico
$6K -$130K -13,062 -96%
CSS
68
Cubist Systematic Strategies
Connecticut
$1K +$1.45K +146 New
IM
69
Islet Management
New York
-$4.88M -491,940 Closed
PAMP
70
Polar Asset Management Partners
Ontario, Canada
-$3.9M -392,808 Closed
Wellington Management Group
71
Wellington Management Group
Massachusetts
-$2.13M -215,024 Closed
DCP
72
Diameter Capital Partners
New York
-$1.19M -119,700 Closed
BCM
73
Basso Capital Management
Connecticut
-$583K -58,718 Closed
MSU
74
Mizuho Securities USA
New York
-$362K -36,490 Closed
TAL
75
TIG Advisors LLC
New York
-$231K -23,238 Closed

TLSI Hedge Fund Activity: Q4 2021 in Review

68 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q4 2021, worth a combined $198M — down 2% from $202M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new TLSI positions and 8 closed out — a net gain of 3 holders — while 8 added to existing stakes and 18 trimmed.

The largest buyer was Weiss Asset Management, adding an estimated $9.32M. The largest seller was Islet Management, exiting entirely with an estimated $4.88M sold.

  • 68 institutional investors held TriSalus Life Sciences (TLSI) as of Q4 2021, up from 66 in Q3 2021.
  • Funds reported $198M of TriSalus Life Sciences stock for Q4 2021, down 2% quarter-over-quarter.
  • 11 funds opened new TriSalus Life Sciences positions in Q4 2021 and 8 closed out, a net change of +3 holders.
  • The largest TriSalus Life Sciences buyer in Q4 2021 was Weiss Asset Management, an estimated $9.32M added.
  • The largest TriSalus Life Sciences seller in Q4 2021 was Islet Management, an estimated $4.88M sold.

Based on aggregated 13F filings for Q4 2021.